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dataset will evolve over time as more data become available. 
Secondly, “classical” trial end points such as overall and 
progression free survival may not be the most appropriate 
outcome measures in elderly-specific trials. Given the limited 
life expectancy, QoL is essential to take into account, and 
also, cost-effectiveness will be different from the general 
population. This makes quality adjusted survival, measured in 
quality adjusted life years (QALYs), a more suitable end 
point, allowing the answer to both questions: it reflects both 
the quantity of lifetime gained and the value of this time, 
and it provides a direct outcome measure to calculate the 
cost-effectiveness of the treatment. In order to calculate 
QALYs, utility scores should be collected prospectively. The 
EuroQoL 5 Dimensions (EQ-5D), a short questionnaire 
consisting of five questions, is most frequently used for this 
purpose.  
General and disease specific quality of life, toxicity and 
preservation of functional capacity are interesting secondary 
end points, scored with a uniform and internationally 
acknowledged scoring system. The additional use of the 
elderly specific questionnaire EORTC QLQ-ELD15 is 
recommended, which has recently been validated 
internationally (Wheelwright, Br J Cancer 2013).   
Results from surveys indicate that the large majority of 
elderly patients would be willing to participate in trials 
(Comis, JCO 2003; Townsley BMC Cancer 2006), but care 
should be taken to limit the complexity of the trial design 
and burden of study related examinations. 
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Purpose/Objective: Online adaptive MR-IGRT was recently 
implemented at our institution. We report workflow 
considerations and initial clinical experience with online 
adaptive MR-IGRT for abdominopelvic malignancies. 
Materials and Methods: The first clinically deployed online 
adaptive MR-IGRT system consists of a split 0.35T MR scanner 
straddling a ring gantry with three MLC-equipped 60Co heads. 
The unit is supported by a fast Monte Carlo based treatment 
planning system allowing real-time adaptive planning with 
the patient on the table. All patients undergo CT- and MR-
simulation for initial treatment planning. A high-resolution 
volumetric MR image is acquired for each patient at the time 
of daily treatment setup. Deformable registration is 
performed using the original simulation CT dataset from 
initial treatment planning, which allows the transfer of the 
initial contours and the electron density map to the 
localization MR of the day. The deformed electron density 
map is then used to recalculate the original plan on the 
anatomy of the day for physician evaluation. Physician re-
contouring and plan re-optimization are performed when 
required, and patient-specific quality assurance is performed 
using an independent Monte Carlo calculation for online 
adaptive QA. The tool also allows for verification of plan 
parameters against the original plan. 
Results: Online adaptive MR-IGRT was implemented in 
September of 2014. Five patients with abdominopelvic 
malignancies have been treated with planned evaluation for 
treatment adaptation in the first 2 months. The clinical 
setting included neoadjuvant rectosigmoid (n=3), 
unresectable gastric, and unresectable pheochromocytoma. 
MR localization images were used to recalculate dose online 
for all cases. Re-contouring and re-optimization was deemed 
necessary for 3/5, while the initial plan deemed sufficient for 
2/5 cases. Reasons for plan adaptation included change in 
target size, weight loss, and change in small bowel anatomy. 
The approximate times required for online dose calculation, 
re-contouring, re-optimization, and QA were 2, 15, 2, and 5 
minutes, respectively. Treatment utilizing the online 
adaptive plan was completed successfully for all cases when 
deemed necessary. 
Conclusions: Online adaptive MR-IGRT has been successfully 
implemented with planning and QA workflow suitable for 
routine clinical application. Clinical trials are in development 
to formally evaluate adaptive treatment of bladder, 
pancreatic, and oligometastatic abdominal malignancies. 
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Purpose/Objective: Several authors have recommended a 2 
mm tolerance for MLC positioning in sliding window 
treatments. A tolerance of 5mm is typically used in VMAT 
treatments, but the optimal value for this technique remains 
unknown. In this paper we present the results of a 
multicentric study to determine the optimal tolerance for 
both techniques. 
Materials and Methods: The procedure used to investigate 
the optimal tolerance is based on dynalog file analysis. The 
study was performed with seven Varian linear accelerators 
(linacs) (Varian Medical Systems, Inc., Palo Alto, CA) from 
five different centers. All linacs were equipped with dynamic 
MLCs: six with the Millennium120 model and one with the 
high definition HD120 model. Dynalogs were collected from 
over 100,000 clinical treatments and an in-house software 
was developed for dynalog analysis. By using this software 
the number of tolerance faults was computed as a function of 
the user-defined tolerance and the optimal value for this 
tolerance tolerance –defined as the lowest achievable value- 
